Dexamethasone treatment to alleviate immunopathology of severe COVID-19 has been shown to induce the depletion of IFN-stimulated neutrophils [208], while the high level of NET production by neutrophils escapes modulation by dexamethasone treatment [215]. Here, IFNA1 is linked to COVID-19.